Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study

Yuichi Kojima, Hideyoshi Kaga, Shinu Hayashi, Toru Kitazawa, Yuko Iimura, Makoto Ohno, Michiyasu Yoshitsugu, Mutsunori Fujiwara, Toru Hiyoshi

Yuichi Kojima, Hideyoshi Kaga, Shinu Hayashi, Toru Kitazawa, Yuko Iimura, Makoto Ohno, Michiyasu Yoshitsugu, Mutsunori Fujiwara, Toru Hiyoshi

Author contributions: Kojima Y, Kaga H, Hayashi S, Kitazawa T, Iimura Y and Fujiwara M contributed to research design; Kojima Y, Ohno M, Yoshitsugu M and Hiyoshi T collected the data; Kojima Y wrote the manuscript; Kaga H, Hayashi S, Kitazawa T, Iimura Y, Ohno M, Yoshitsugu M, Fujiwara M and Hiyoshi T contributed to revising the manuscript; and all authors approved the final version.

Correspondence to: Yuichi Kojima, MD, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan. kojima_yuichi@med.jrc.or.jp
Telephone: +81-3-34001311  Fax: +81-3-34091604
Received: September 12, 2011  Revised: November 29, 2012
Accepted: January 5, 2013
Published online: February 15, 2013

Abstract

AIM: To assess the effects of sitagliptin and nateglinide on lipid metabolism.

METHODS: In a parallel group comparative open trial, patients with type 2 diabetes mellitus under treatment at the Japanese Red Cross Medical Center were randomly assigned to receive either sitagliptin (50 mg once daily) or nateglinide (90 mg three times daily before meals). Eligible patients met the following criteria: age ≥ 20 years; hemoglobin A1c (HbA1c) > 6.5% despite diet and exercise; HbA1c between 6.5% and 8.0%; fasting glucose < 7.77 mmol/L; diet and exercise therapy for more than 3 mo; and ability to read and understand the information for written informed consent. Exclusion criteria were contraindications to sitagliptin, contraindications to nateglinide, pregnancy or possible pregnancy, and severe liver/renal failure. Patients who were considered to be unsuitable by the attending physician for other reasons were also excluded. Blood samples were collected at one and three hours after intake of a test meal. The primary outcome measure was the area under the curve (AUC) of apolipoprotein (Apo) B48 at three hours postprandially.

RESULTS: Twenty patients were randomly assigned to the sitagliptin group and sixteen patients were randomized to the nateglinide group. All 36 patients took the medication as directed by the physician in both groups, and they all were analyzed. Apart from anti-diabetic drugs, there was no difference between the two groups with respect to the frequency of combined use of lipid-lowering, antihypertensive, and/or anti-platelet drugs. The doses of these medications were maintained during 12 wk of treatment. Detailed dietary advice, together with adequate exercise therapy, was given to the patients so that other factors apart from the two test drugs were similar in the two groups. There were no significant differences of the baseline characteristics between the two groups, except for body mass index (the sitagliptin group: 25.14 ± 3.05 kg/m²; the nateglinide group: 21.39 ± 2.24 kg/m²). Fasting levels of HbA1c, glycated albumin, 1.5-anhydroglucitol, and blood glucose, as well as the blood glucose levels at one and three hours postprandially, improved in both groups after 12 wk of treatment, and there were no significant differences between the two groups. However, the glucagon level at one hour postprandially (P = 0.040) and the diastolic blood pressure (P < 0.01) only showed a significant decrease in the sitagliptin group. In the nateglinide group, there was no significant change in the AUC of Apo B48, the glucagon level at one hour postprandially, the fasting triglyceride level, or the diastolic blood pressure. Body weight was unchanged in both groups. However, the AUC of Apo B48 at three hours postprandially showed a significant decrease in the sitagliptin group from 2.48 ± 0.11 at baseline to 1.94 ± 0.78 g/L per hour after 12 wk (P = 0.019). The fasting triglyceride level also decreased significantly in the sitagliptin group (P
INTRODUCTION

When treating diabetes mellitus, prevention of major vascular disorders is an important objective. Several studies have demonstrated that postprandial hyperglycemia (PPHG) is significantly linked to major vascular disorders. In an in vitro study of human vascular endothelial cells, the cellular death rate was increased by repeated fluctuation between normoglycemia and hyperglycemia compared with that due to persistent hyperglycemia. These findings suggest that inhibition of circadian glycemic changes may prevent vascular disorders.

Postprandial hyperlipidemia (PPHL) has been noted in patients with type 2 diabetes. Inhibition of lipoprotein lipase activity due to impaired insulin action on adipocytes and an increase of exogenous lipoproteins due to overeating are considered to be the underlying causes of PPHL. PPHL may trigger progression of arteriosclerosis with the accumulation of chylomicron remnants in the vessel walls. An epidemiological study of Japanese patients has shown that hypertriglyceridemia is an independent risk factor for coronary artery disorders.

Nateglinide, a D-phenylalanine derivative, rapidly stimulates insulin secretion to exert an antihyperglycemic effect and treatment with nateglinide inhibits carotid artery intima-media thickening, which is a surrogate marker of arteriosclerosis. On the other hand, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin increases insulin secretion by inhibiting breakdown of incretins, thereby exerting an antihyperglycemic effect. The efficacy of sitagliptin for PPHL has also been reported. However, it is unknown whether this improvement of PPHL is due to suppression of postprandial glycaemia or an increase of incretin secretion secondary to inhibition of DPP-4.

In the present study, we treated type 2 diabetic patients with nateglinide or sitagliptin for 12 wk. The response to a test meal was assessed to compare the effects of the two drugs on PPHG and PPHL.

MATERIALS AND METHODS

Study population

Patients with type 2 diabetes attending the Japanese Red Cross Medical Center (JRCMC) between July 2010 and June 2011 were enrolled in this parallel group comparative open trial. Eligible patients met the following criteria: age ≥ 20 years; hemoglobin A1c (HbA1c) > 6.5% despite diet and exercise; HbA1c between 6.5% and 8.0%; fasting glucose < 7.77 mmol/L; diet and exercise therapy for more than 3 mo; and ability to read and understand the information for written informed consent. Exclusion criteria were contraindications to sitagliptin, contraindications to nateglinide, pregnancy or possible pregnancy, and severe liver/renal failure. We also excluded patients who were considered to be unsuitable by the attending physician for other reasons. As many patients as possible were registered because it was difficult to set a specific sample size for this exploratory clinical study and relevant information was limited.

Randomization

Random allocation of patients to either treatment group was performed centrally by using our registration system, with the random allocation sequence being generated by Kojima Y. Enrollment was done by Kojima Y, Kaga H and Kitazawa T, while assignment of participants to interventions was carried out by Imura Y, Ohno M, Yoshitsugu M and Hiyoshi T.

Study treatment

Sitagliptin was administered at a dose of 50 mg once daily before breakfast to one group, while nateglinide was administered at a dose of 90 mg three times daily (immediately before each meal) to the other group. Doses of antihypertensive and lipid-lowering drugs were not changed during the study.

Data collection

Blood samples were collected before and one and three hours after eating a test meal (total energy: 1925 kJ; protein: 18.0 g, fat: 18.0 g, carbohydrate: 56.5 g), both before and immediately after the 12-wk treatment period (final date: September 30, 2011). Then the levels of various parameters of glucose and lipid metabolism were measured.

Outcome measures

The primary outcome was the area under the concentration vs time curve (AUC) of apolipoprotein (Apo) B48 at three hours postprandially after 12 wk of treatment. The secondary outcomes were postprandial blood glucose, HbA1c, glucagon at one hour postprandially, fasting triglycerides, and blood pressure.


Table 1 Baseline patient profile and post-treatment data

|                      | Sitagliptin group | Nateglinide group |
|----------------------|-------------------|-------------------|
|                      | Before treatment  | After 3 mo of treatment | Before treatment  | After 3 mo of treatment |
| Age (yr)             | 63.85 ± 12.92     | -                  | 66.44 ± 9.02      | -                      |
| Sex: M/F (n)         | 15/5              | 15/5              | 12/4              | 12/4                   |
| Body weight (kg)     | 68.79 ± 12.89     | 69.30 ± 13.18     | 58.36 ± 8.54      | 58.75 ± 8.52           |
| Systolic blood pressure (mmHg) | 134.3 ± 19.3 | 126.5 ± 11.1      | 129.1 ± 13.9      | 122.7 ± 14.8           |
| Diastolic blood pressure (mmHg) | 81.5 ± 12.9 | 73.3 ± 7.4\(^4\) | 76.9 ± 8.8        | 74.3 ± 10.2            |
| HbA\(^1c\) (%)       | 7.2 ± 0.7         | 7.0 ± 0.8\(^5\)  | 7.2 ± 0.4         | 6.8 ± 0.3\(^6\)       |
| Glycated albumin (%) | 19.3 ± 3.6        | 17.7 ± 2.4\(^6\) | 19.7 ± 3.4        | 18.1 ± 2.8\(^3\)      |
| 1.5-AG (mmol/L)      | 65.5 ± 45.8       | 81.6 ± 46.2\(^2\) | 51.0 ± 22.7       | 69.5 ± 29.3\(^b\)     |
| Fasting blood glucose (mmol/L) | 7.8 ± 1.7 | 7.3 ± 1.6         | 8.1 ± 1.0         | 7.6 ± 1.5              |
| Blood glucose 1 h postprandially (mmol/L) | 12.0 ± 3.0 | 10.6 ± 3.1\(^1\) | 13.6 ± 2.3        | 11.0 ± 2.8\(^8\)      |
| Blood glucose 3 h postprandially (mmol/L) | 7.6 ± 2.5 | 6.6 ± 2.0\(^3\)  | 7.6 ± 2.5         | 6.5 ± 1.9\(^9\)       |
| Apo-B48 AUC (g/L per hour) | 2.48 ± 0.11 | 1.94 ± 0.78\(^8\) | 3.14 ± 0.29       | 2.29 ± 0.16            |
| Apo-A1 AUC (g/L per hour) | 4.64 ± 0.73 | 4.50 ± 0.76       | 4.59 ± 0.73       | 4.67 ± 0.76            |
| Apo-B AUC (g/L per hour) | 2.73 ± 0.47 | 2.91 ± 0.46       | 2.60 ± 0.46       | 2.64 ± 0.40            |
| Apo-C3 AUC (g/L per hour) | 0.30 ± 0.07 | 0.28 ± 0.06       | 0.31 ± 0.11       | 0.28 ± 0.09            |
| Fasting insulin (pmol/L) | 53.3 ± 26.9 | 58.4 ± 34.4       | 41.3 ± 29.0       | 40.4 ± 31.5            |
| Insulin 1 h postprandially (μU/mL) | 279.3 ± 115.7 | 275.1 ± 143.4 | 230.1 ± 104.2 | 248.7 ± 112.2 |
| Fasting glucagon (ng/L) | 67.2 ± 15.9 | 66.6 ± 16.0       | 65.1 ± 16.4       | 70.1 ± 16.0            |
| Glucagon 1 h postprandially (ng/L) | 80.3 ± 17.0 | 70.3 ± 16.9\(^9\) | 79.0 ± 13.4       | 81.5 ± 20.6            |
| Fasting triglycerides (mmol/L) | 1.26 ± 0.81 | 1.09 ± 0.61\(^1\) | 1.54 ± 1.44       | 1.11 ± 0.60            |

\(^1\)This parameter showed a significant between-group difference (P < 0.05) before treatment. Data are shown as the mean ± SD (P < 0.05, \(^a\)P < 0.01 vs time curve). Area under the concentration vs time curve (AUC) data were obtained from before to three hours after the test meal. The t-test was used for statistical analysis. M: Male; F: Female; 1.5-AG: 1.5-anhydroglucitol; Apo: Apolipoprotein; HbA\(^1c\): Hemoglobin A\(^1c\).
No adverse events, including hypoglycemia, gastrointestinal side effects, pancreatitis, infection, immune abnormalities, liver dysfunction, renal dysfunction, and cardiac dysfunction, occurred in either group.

DISCUSSION

The present study showed that two oral antidiabetic drugs with different mechanisms of action similarly improved postprandial glycemia and significantly decreased the levels of HbA1c, glycated albumin, and 1.5-AG. With regard to lipid metabolism, however, a significant decrease of fasting triglycerides and of the postprandial AUC for Apo B48, a marker of chylomicrons and chylomicron remnants (exogenous lipids), only occurred in the sitagliptin group. There was no change of the AUC for Apo B (endogenous lipids) in either group.

Tremblay et al\[23\] investigated postprandial changes of lipoproteins after administration of sitagliptin for 6 wk and reported a significant decrease of triglyceride-rich lipoproteins (both Apo B and Apo B48), suggesting that sitagliptin reduced the levels of endogenous and exogenous lipids. In contrast, our study showed that Apo B did not decrease after 12 wk of treatment with sitagliptin, while Apo B48 decreased significantly. This difference may be explained by different conditions of the two studies, including the lipid and calorie contents of the test meals. Apo C3 is related to inhibition of lipoprotein lipase activity in hepatic cells, and it showed no significant change in either group, which suggests that the Apo C3-related pathway for synthesis of endogenous lipids was not affected by either medication. In the sitagliptin group, it is thought that inhibition of gastrointestinal peristalsis leads to reduced absorption of triglycerides and decreased Apo B48 synthesis.

Lee et al\[26\] investigated the serum glucagon levels of healthy individuals and patients with impaired glucose tolerance or type 2 diabetes and reported that the differences between these groups were maximal at one hour postprandially. In the present study, a significant decrease of the serum glucagon level at one hour postprandially was only noted in the sitagliptin group, suggesting that sitagliptin and nateglinide have differing effects on glucagon. In addition, the influence of glucagon on postprandial lipid levels requires further investigation.

Nateglinide has been reported to improve PPHG through its insulinotropic action, and nateglinide treatment caused no appreciable changes of serum lipid levels in this study. The emphasis of treatment for type 2 diabetes has shifted from simple correction of fasting and PPHG to management of dyslipidemia as well. Because sitagliptin inhibits both PPHG and PPHL, it may be useful for the prevention of macrovascular disease in patients with diabetes\[23-29\], but a large-scale prospective study would be required for confirmation.

This study had the following limitations: (1) small sample sizes (20 and 16 per group, respectively); (2) unequal baseline body weights of the two groups; and (3) a short follow-up period of 3 mo. Accordingly, our results have limited generalizability and a large-scale long-term study is needed to verify our findings.

In conclusion, our randomized controlled trial showed that suppression of triglycerides and postprandial Apo B48 only occurred in the sitagliptin group, although PPHG was similarly improved in both the sitagliptin and nateglinide groups. To best of our knowledge, this is the first report to confirm the efficacy of a DPP-4 inhibitor for improving postprandial hyperlipidemia while achieving a comparable improvement of blood glucose to the control drug. A large-scale prospective study of sitagliptin therapy is needed.

COMMENTS

Background

There have been some reports about the efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, for postprandial hyperlipidemia in patients with type 2 diabetes. However, it is unknown whether this improvement of postprandial hyperlipidemia is due to suppression of postprandial glycemia or an increase of incretin secretion secondary to inhibition of DPP-4.

Research frontiers

Nateglinide, a D-phenylalanine derivative, rapidly stimulates insulin secretion to exert its antihyperglycemic effect. Sitagliptin was the first incretin enhancer approved in Japan (in 2009) and it increases insulin secretion by inhibiting the breakdown of incretins, unlike nateglinide. It remains unclear which of these two drugs is more effective for improving postprandial hyperlipidemia and hyperglycemia.

Innovations and breakthroughs

This is the first study to demonstrate that sitagliptin significantly improves some lipid parameters while having a comparable effect on blood glucose to nateglinide, with a decrease of triglycerides and apolipoprotein (Apo) B48 only being observed in patients receiving sitagliptin.

Applications

By understanding and utilizing the response to sitagliptin demonstrated in this study, treatment of diabetes could be better tailored and macrovascular disease may also be prevented because sitagliptin inhibits both postprandial hyperglycemia and postprandial hyperlipidemia.

Terminology

DPP-4 inhibitors, of which sitagliptin was the first to be released in Japan, inhibit the enzyme DPP-4 and are used to treat type 2 diabetes. Apo B is the major component of the apolipoproteins, which serve as enzyme cofactors, receptor ligands, and lipid carriers that regulate the metabolism of lipoproteins and their tissue uptake.

Peer review

In this 12-wk trial, the authors tested the effects of sitagliptin and nateglinide on metabolic markers in 36 patients with type 2 diabetes (n = 20 and n = 16, respectively). While postprandial blood glucose and hemoglobin A1c improved in both groups, only sitagliptin improved the lipid profile at 1 or 3 h postprandially. Although its small size is a major limitation of this study, the results provide some interesting information about the metabolic effects of these two drugs in diabetic patients.

REFERENCES

1 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117 [PMID: 7587918 DOI: 10.1016/0168-8227(95)01064-K]

2 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk
of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853. [PMID: 9742976 DOI: 10.1016/S0140-6736(98)01919-6]

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589. [PMID: 18784090 DOI: 10.1056/NEJMoa0806470]

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Guthrie S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. [PMID: 18599178 DOI: 10.1056/NEJMoa0802743]

Duckworth W, Abraira C, Morritz T, Reda D, Emanuele N, Reaven PG, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson GW, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139. [PMID: 19092145 DOI: 10.1056/NEJMoa0808431]

Patel A, MacMahon S, Chalmers J, Neil B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoin S, de Galan BE, Joshi R, Trusell F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. [PMID: 18559916 DOI: 10.1056/NEJMoa0802987]

Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, Sharp SJ, Simmons RK, van den Donk WA, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson GW, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772. [PMID: 19465231]

Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-612. [PMID: 19427768]

Glucose tolerance and mortality: comparison of WHO and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005; 28: 2626-2632. [PMID: 16249530 DOI: 10.2337/diabetes.28.11.2626]
27 Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. *Lancet* 2012; 380: 475-483 [PMID: 22748821 DOI: 10.1016/S0140-6736(12)60691-6]

28 Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. *Postgrad Med* 2010; 122: 16-27 [PMID: 20463410 DOI: 10.310/pgm.2010.05.2138]

29 Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. *BMC Endocr Disord* 2010; 10: 7 [PMID: 20412573]

P- Reviewers Brunetti A, Qi L  S- Editor Song XX  L- Editor A  E- Editor Li JY